The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

被引：1

作者：

Gier, Chad ^{[1
]}

Gilchrist, Ian ^{[1
]}

Fordham, Matthew ^{[1
]}

Riordan, Luke ^{[1
]}

Milchan, Ella ^{[2
]}

Patel, Nidhi ^{[2
]}

Mohedi, Azad ^{[2
]}

Choudhury, Sahana ^{[1
]}

Kits, Tara ^{[1
]}

Cohen, Regina ^{[1
]}

Doughtery, Joseph ^{[1
]}

Reilly, John P. ^{[1
]}

Kalogeropoulos, Andreas ^{[1
]}

Rahman, Tahmid ^{[1
]}

Chen, On ^{[1
]}

机构：

[1] Stony Brook Univ Hosp, Stony Brook Heart Inst, Stony Brook, NY 11794 USA

[2] Stony Brook Renaissance Sch Med, Stony Brook, NY USA

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2024年 / 11卷

关键词：

hyperlipidemia; quality improvement; ASCVD; lipid lower medications; LDL-Cholesterol; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; BEMPEDOIC ACID; EFFICACY; SAFETY;

D O I：

10.3389/fcvm.2024.1284562

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.

引用

页数：6

共 31 条

[1] Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, Semira Abdi
Hussain, Nadia
Elnor, Asim Ahmed
Said, Amira S. A.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2021, 26 (05) : 437 - 452
[2] Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, Stephen J.
Nelson, Adam J.
CURRENT ATHEROSCLEROSIS REPORTS, 2025, 27 (01)
[3] The Role of Non-statin Lipid-Lowering Medications in Youth with Hypercholesterolemia
Butt, Waleed Z.
Yee, Jennifer K.
CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (05) : 379 - 389
[4] Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies
Parag Goyal
Leon I. Igel
Keith LaScalea
William B. Borden
Current Atherosclerosis Reports, 2014, 16
[5] Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies
Goyal, Parag
Igel, Leon I.
LaScalea, Keith
Borden, William B.
CURRENT ATHEROSCLEROSIS REPORTS, 2014, 16 (02)
[6] The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention
Kamanu, Chukwuemezie
Karalis, Dean G.
CURRENT ATHEROSCLEROSIS REPORTS, 2025, 27 (01)
[7] Traditional and novel non-statin lipid-lowering drugs
Jain, Peeyush
INDIAN HEART JOURNAL, 2024, 76 : S38 - S43
[8] Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Collins, Patrick D.
Sattar, Naveed
CURRENT CARDIOLOGY REPORTS, 2016, 18 (12)
[9] Early Management of Blood Lipid Levels with Non-Statin Lipid-Lowering Drugs in Acute Coronary Syndrome: A Mini Review
Chen, Chen
Wei, Fang-Fei
Dong, Yugang
Liu, Chen
CARDIOVASCULAR DRUGS AND THERAPY, 2024,
[10] Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression
Masson, Walter
Lobo, Martin
Siniawski, Daniel
Molinero, Graciela
Masson, Gerardo
Huerin, Melina
Nogueira, Juan Patricio
LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)

← 1 2 3 4 →